| Outcome Measures: |
Primary: urinary albumin/creatinine ratio, Change in albuminuria defined as urinary albumin/creatinine ratio: UACR) with dapagliflozin 10mg/d for 24 weeks relative to placebo, 24 weeks | Secondary: systolic and diastolic blood pressure, Change in systolic and diastolic blood pressure: effect of dapagliflozin 10mg/d compared to placebo on change in systolic and diastolic blood pressure, 24 weeks|body weight, change in body weight: effect of dapagliflozin 10mg/d compared to placebo on change in body, 24 weeks|HbA1c, change in HbA1c: effect of dapagliflozin 10mg/day compared to placebo on change in HbA1c, 24 weeks|eGFR, change in eGFR: effect of dapagliflozin 10mg/day compared to placebo on change in eGFR, 24 weeks|change in UACR, difference in proportion of patients with ≥30%, 40%, 50% change in UACR from baseline at week 24.: effect of dapagliflozin 10mg/day compared to placebo on the proportion of patients with ≥30%, 40%, 50% change in UACR, 24 weeks|number of SAE's and AE's, Safety of dapagliflozin vs Placebo: number of SAE's and AE's reported by the subject or investigator if qualified as: reason for discontinuation, volume depletion, fracture, diabetic ketoacidosis, amputation and adverse events leading to amputation, urinary tract infection, genital infections and hypoglycemia, 24 weeks
|
